StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
OMDA$18.38+2.28%
Fair $18.38+0.0%

OMDA

Omada Health, Inc.

Healthcare / Health Information ServicesNasdaqGS

$18.38

+0.41 (+2.28%)

Fairly Valued+0.0%Fair Value $18.38Fund rank 25/100 · Data gapFallback financials|
SA 27/D
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-38.0M · quality 42.7/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 23/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

27/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -5.6%, below the 5% threshold
Thesis & Journal · OMDALocal privado en este navegador · Omada Health, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.1B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-5.6%

↓

Gross Margin

65.7%

↑

Debt/Equity

N/A

•
52-Week Range$18
$10$28

TradingView lightweight chart

OMDA price, volumen y niveles de valoración

Último $18.38Periodo -20.1%
Fair value: $18.38

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+42.9%

FCF CAGR

—

FCF margin

4.8%

FCF / Net income

-0.97x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $260.2M · net income $-12.8M · FCF $12.4M

2022-FY → 2025-FY

Gross margin

65.7%+17.7% pts

Operating margin

-4.6%+76.5% pts

Net margin

-4.9%+76.4% pts

FCF margin

4.8%+85.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$260.2M$260.2M$169.8M$122.8M$89.2M
Net Income$-12.8M$-12.8M$-47.1M$-67.5M$-72.5M
EBITDA$-4.8M$-4.8M$-37.8M$-58.4M$-64.0M
EPS-0.35-0.35-0.85-1.41-1.52
Gross Margin65.7%65.7%60.6%57.0%48.0%
Operating Margin-4.6%-4.6%-25.7%-53.8%-81.1%
Net Margin-4.9%-4.9%-27.8%-55.0%-81.3%
Balance Sheet
Debt/Equity——-0.080.310.20
Current Ratio3.923.92———
Cash Flow
Free Cash Flow$12.4M$12.4M$-38.0M$-52.7M$-71.7M
Returns
ROE-5.6%-5.6%12.3%-68.2%-46.6%
Valuation
P/B2.932.93———
Growth & Yield
Revenue Growth53.2%53.2%38.3%37.7%—
EPS Growth58.6%58.6%40.2%6.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total -20.1%

Total return

-20.1%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.85 → -0.35

Residual

-20.1%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-20.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.